Halozyme Therapeutics (NASDAQ:HALO) Updates FY 2026 Earnings Guidance

Halozyme Therapeutics (NASDAQ:HALO) issued an update on its FY 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 8.650-9.000 for the period, compared to the consensus EPS estimate of 8.020. The company issued revenue guidance of $1.8 billion-$1.9 billion, compared to the consensus revenue estimate of $1.8 billion.

Halozyme Therapeutics Trading Up 2.6%

Halozyme Therapeutics stock opened at $85.76 on Friday. The company has a quick ratio of 2.33, a current ratio of 2.76 and a debt-to-equity ratio of 8.81. The stock has a market cap of $10.17 billion, a P/E ratio of 30.85, a P/E/G ratio of 0.35 and a beta of 0.85. The company’s fifty day simple moving average is $75.74 and its 200-day simple moving average is $71.25. Halozyme Therapeutics has a 12 month low of $61.22 and a 12 month high of $86.00.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The business had revenue of $481.00 million during the quarter, compared to the consensus estimate of $402.28 million. During the same period in the prior year, the firm earned $1.54 EPS. Halozyme Therapeutics’s quarterly revenue was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, sell-side analysts forecast that Halozyme Therapeutics will post 7.54 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on HALO. Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. UBS Group reiterated a “buy” rating and issued a $90.00 price target on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. Weiss Ratings raised Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday, July 31st. Morgan Stanley decreased their target price on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research report on Tuesday, May 12th. Finally, HC Wainwright raised their target price on shares of Halozyme Therapeutics from $95.00 to $115.00 and gave the company a “buy” rating in a research note on Friday. Eight investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Halozyme Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $83.60.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Mahesh Krishnan sold 7,304 shares of Halozyme Therapeutics stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $75.00, for a total value of $547,800.00. Following the completion of the sale, the director owned 14,462 shares in the company, valued at $1,084,650. The trade was a 33.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $76.71, for a total transaction of $124,653.75. Following the transaction, the director directly owned 42,044 shares in the company, valued at $3,225,195.24. This represents a 3.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 72,477 shares of company stock worth $5,102,643. Corporate insiders own 2.50% of the company’s stock.

Key Headlines Impacting Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Record quarterly results exceeded expectations. Second-quarter revenue rose 48% year over year to $481 million, beating estimates of approximately $402 million. Adjusted earnings reached $2.28 per diluted share, above consensus estimates ranging from $1.79 to $1.82 and up from $1.54 a year earlier. Halozyme Reports Record Second Quarter 2026 Results
• Positive Sentiment: Royalty growth remained a key catalyst. Royalty revenue increased 50% year over year to $308 million, highlighting continued commercial adoption of Halozyme’s drug-delivery technologies and the scalability of its royalty-based business. Halozyme Q2 Key Metrics
• Positive Sentiment: Management raised 2026 guidance. Halozyme now expects total revenue of $1.835 billion to $1.910 billion, royalty revenue of $1.220 billion to $1.245 billion, adjusted EBITDA of $1.225 billion to $1.280 billion, and non-GAAP EPS of $8.65 to $9.00. The EPS outlook is well above the roughly $8.02 analyst consensus. Halozyme Q2 2026 Results Presentation
• Positive Sentiment: Business development exceeded targets. The company signed five new ENHANZE and Hypercon collaboration agreements during 2026, already surpassing its goal of three agreements for the full year. This could strengthen Halozyme’s longer-term pipeline and royalty growth prospects. Halozyme Q2 2026 Earnings Call Transcript

Hedge Funds Weigh In On Halozyme Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of HALO. Larson Financial Group LLC boosted its position in Halozyme Therapeutics by 3,118.2% during the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 343 shares during the last quarter. Wexford Capital LP purchased a new stake in Halozyme Therapeutics in the 3rd quarter valued at about $70,000. Employees Retirement System of Texas boosted its holdings in shares of Halozyme Therapeutics by 64.6% in the 3rd quarter. Employees Retirement System of Texas now owns 1,088 shares of the biopharmaceutical company’s stock worth $80,000 after buying an additional 427 shares during the last quarter. UMB Bank n.a. increased its stake in shares of Halozyme Therapeutics by 18.2% during the 4th quarter. UMB Bank n.a. now owns 1,296 shares of the biopharmaceutical company’s stock worth $87,000 after purchasing an additional 200 shares during the last quarter. Finally, Smartleaf Asset Management LLC raised its stake in shares of Halozyme Therapeutics by 21.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,399 shares of the biopharmaceutical company’s stock valued at $95,000 after buying an additional 251 shares during the period. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.